Condition: Acute Myeloid Leukemia · Myelodysplastic Syndromes · Myelodysplastic/Myeloproliferative Neoplasm · Sponsor: BeOne Medicines
The study will determine the safety, tolerability, recommended Phase 2 dose (RP2D) and preliminary efficacy of BGB-11417 as monotherapy and in combination with azacitidine in participants with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)or MDS/myeloproliferative neoplasm (MPN) .
This description comes directly from the study's public registry record.
Study Director · 1.877.828.5568 · clinicaltrials@beonemed.com
Always discuss trial participation with your own doctor first.
| City of Hope National Medical Center | Duarte, California, United States | Terminated |
| Tampa General Hospital | Tampa, Florida, United States | Recruiting |
| Upmc Hillman Cancer Center(Univ of Pittsburgh) | Pittsburgh, Pennsylvania, United States | Recruiting |
| Md Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
| Concord Repatriation General Hospital | Concord, New South Wales, Australia | Recruiting |
| St George Hospital | Kogarah, New South Wales, Australia | Recruiting |
| Orange Health Hospital | Orange, New South Wales, Australia | Recruiting |
| Gold Coast University Hospital | Southport, Queensland, Australia | Recruiting |
| Monash Health | Clayton, Victoria, Australia | Recruiting |
| St Vincents Hospital Melbourne | Fitzroy, Victoria, Australia | Recruiting |
| Austin Health | Heidelberg, Victoria, Australia | Recruiting |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04771130